Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Schwarz BioSciences; UCB
- 08 Jun 2017 Results of post hoc analysis of pooled data from 6 placebo contolled trials (SP506, SP512, SP513, SP515, SP650, and SP921) presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 08 Jun 2017 Results of post-hoc pooled analysis from patients who received levodopa doses in 8 randomized placebo-controlled studies, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
- 12 Feb 2016 Results of pooled post-hoc analysis of this and two other trials (see profile 169511 and 10814) published in the Clinical Neuropharmacology